Resistance Analyses of Integrase Strand Transfer Inhibitors within Phase 3 Clinical Trials of Treatment-Naive Patients
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Resistance Analyses of Integrase Strand Transfer Inhibitors within Phase 3 Clinical Trials of Treatment-Naive Patients
Authors
Keywords
-
Journal
Viruses-Basel
Volume 6, Issue 7, Pages 2858-2879
Publisher
MDPI AG
Online
2014-07-22
DOI
10.3390/v6072858
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Reliability and Clinical Relevance of the HIV-1 Drug Resistance Test in Patients With Low Viremia Levels
- (2014) Maria Mercedes Santoro et al. CLINICAL INFECTIOUS DISEASES
- Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study
- (2014) Bonaventura Clotet et al. LANCET
- Impact of Primary Elvitegravir Resistance-Associated Mutations in HIV-1 Integrase on Drug Susceptibility and Viral Replication Fitness
- (2013) Michael E. Abram et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- HIV-1 genetic variation and drug resistance development
- (2013) Sarah Megens et al. Expert Review of Anti-Infective Therapy
- A Randomized Double-Blind Comparison of Coformulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Versus Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate for Initial Treatment of HIV-1 Infection
- (2013) Andrew Zolopa et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- A Randomized, Double-Blind Comparison of Coformulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF vs Ritonavir-Boosted Atazanavir Plus Coformulated Emtricitabine and Tenofovir DF for Initial Treatment of HIV-1 Infection
- (2013) Jürgen K. Rockstroh et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- A Randomized, Double-Blind Comparison of Single-Tablet Regimen Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Versus Single-Tablet Regimen Efavirenz/Emtricitabine/Tenofovir DF for Initial Treatment of HIV-1 Infection
- (2013) David A. Wohl et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- A Randomized, Double-blind Comparison of Single-Tablet Regimen Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF vs Ritonavir-Boosted Atazanavir Plus Emtricitabine/Tenofovir DF for Initial Treatment of HIV-1 Infection
- (2013) Nathan Clumeck et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study
- (2013) Pedro Cahn et al. LANCET
- Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study
- (2013) Francois Raffi et al. LANCET
- Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection
- (2013) Sharon L. Walmsley et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical Use of HIV Integrase Inhibitors: A Systematic Review and Meta-Analysis
- (2013) Peter Messiaen et al. PLoS One
- Antiretroviral Treatment of Adult HIV Infection
- (2012) Melanie A. Thompson et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks
- (2012) Paul E Sax et al. LANCET
- Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial
- (2012) Edwin DeJesus et al. LANCET
- Impact of Low-Level-Viremia on HIV-1 Drug-Resistance Evolution among Antiretroviral Treated-Patients
- (2012) Constance Delaugerre et al. PLoS One
- Development of Elvitegravir Resistance and Linkage of Integrase Inhibitor Mutations with Protease and Reverse Transcriptase Resistance Mutations
- (2012) Mark A. Winters et al. PLoS One
- Resistance to HIV integrase inhibitors
- (2012) Thibault Mesplède et al. Current Opinion in HIV and AIDS
- HIV integrase as a target for antiretroviral therapy
- (2012) Daria J. Hazuda Current Opinion in HIV and AIDS
- Transmission of integrase strand-transfer inhibitor multidrug-resistant HIV-1: case report and response to raltegravir-containing antiretroviral therapy
- (2011) Benjamin Young et al. ANTIVIRAL THERAPY
- Transmitted raltegravir resistance in an HIV-1 CRF_AG-infected patient
- (2011) Sarita D Boyd et al. ANTIVIRAL THERAPY
- Evolution in the sensitivity of quantitative HIV-1 viral load tests
- (2011) Bryan R. Cobb et al. JOURNAL OF CLINICAL VIROLOGY
- Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial
- (2011) Joseph J Eron et al. LANCET INFECTIOUS DISEASES
- Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study
- (2011) Jean-Michel Molina et al. LANCET INFECTIOUS DISEASES
- Structural and Functional Analyses of the Second-Generation Integrase Strand Transfer Inhibitor Dolutegravir (S/GSK1349572)
- (2011) S. Hare et al. MOLECULAR PHARMACOLOGY
- HIV-1 Integrase Sequence Variability in Antiretroviral Naïve Patients and in Triple-Class Experienced Patients Subsequently Treated with Raltegravir
- (2010) Vici Varghese et al. AIDS RESEARCH AND HUMAN RETROVIRUSES
- Raltegravir Versus Efavirenz Regimens in Treatment-Naive HIV-1–Infected Patients: 96-Week Efficacy, Durability, Subgroup, Safety, and Metabolic Analyses
- (2010) Jeffrey L Lennox et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Activity of Elvitegravir, a Once‐Daily Integrase Inhibitor, against Resistant HIV Type 1: Results of a Phase 2, Randomized, Controlled, Dose‐Ranging Clinical Trial
- (2010) Andrew R. Zolopa et al. JOURNAL OF INFECTIOUS DISEASES
- Resistance to Integrase Inhibitors
- (2010) Mathieu Métifiot et al. Viruses-Basel
- Strand transfer inhibitors of HIV-1 integrase: Bringing IN a new era of antiretroviral therapy
- (2009) Damian J. McColl et al. ANTIVIRAL RESEARCH
- Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial
- (2009) Jeffrey L Lennox et al. LANCET
- Subgroup and Resistance Analyses of Raltegravir for Resistant HIV-1 Infection
- (2008) David A. Cooper et al. NEW ENGLAND JOURNAL OF MEDICINE
- Natural variation of HIV-1 group M integrase: Implications for a new class of antiretroviral inhibitors
- (2008) Soo-Yon Rhee et al. Retrovirology
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started